Citigroup’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-12,600
| Closed | -$227K | – | 7766 |
|
|
2020
Q2 | $227K | Hold |
12,600
| – | – | ﹤0.01% | 4917 |
|
|
2020
Q1 | $90K | Sell |
12,600
-10,700
| -46% | -$134K | ﹤0.01% | 5433 |
|
|
2019
Q4 | $556K | Sell |
23,300
-2,700
| -10% | -$74.5K | ﹤0.01% | 4338 |
|
|
2019
Q3 | $697K | Sell |
26,000
-10,000
| -28% | -$281K | ﹤0.01% | 4014 |
|
|
2019
Q2 | $977K | Buy |
36,000
+4,100
| +13% | +$129K | ﹤0.01% | 3662 |
|
|
2019
Q1 | $1.11M | Buy |
31,900
+7,300
| +30% | +$211K | ﹤0.01% | 3282 |
|
|
2018
Q4 | $480K | Buy |
24,600
+500
| +2% | +$10.3K | ﹤0.01% | 4163 |
|
|
2018
Q3 | $642K | Sell |
24,100
-33,500
| -58% | -$1.09M | ﹤0.01% | 3988 |
|
|
2018
Q2 | $2.17M | Buy |
57,600
+32,100
| +126% | +$1.23M | ﹤0.01% | 2616 |
|
|
2018
Q1 | $833K | Buy |
25,500
+3,300
| +15% | +$145K | ﹤0.01% | 3438 |
|
|
2017
Q4 | $1.08M | Buy |
22,200
+1,700
| +8% | +$86K | ﹤0.01% | 3267 |
|
|
2017
Q3 | $1.11M | Buy |
20,500
+8,400
| +69% | +$493K | ﹤0.01% | 3261 |
|
|
2017
Q2 | $680K | Sell |
12,100
-800
| -6% | -$32K | ﹤0.01% | 3698 |
|
|
2017
Q1 | $506K | Buy |
12,900
+2,000
| +18% | +$63.7K | ﹤0.01% | 3858 |
|
|
2016
Q4 | $245K | Buy |
10,900
+10,500
| +2,625% | +$205K | ﹤0.01% | 5114 |
|
|
2016
Q3 | $9K | Buy |
+400
| New | +$9.39K | ﹤0.01% | 6597 |
|
Citigroup's PTLA Position: Q3 2020 in Review
Citigroup sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 1,770,806 shares — an estimated $31.9M sold.
Citigroup first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $41.4M in Q4 2015. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Citigroup reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Citigroup sold 1,770,806 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $31.9M.
- Citigroup first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Citigroup's Portola Pharmaceuticals, Inc. position peaked at $41.4M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Citigroup's 13F filing for Q3 2020, filed 12 Nov 2020.